Purpose. The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed. Summary. AI therapy has become a standard of care for the treatment of ...

In a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...

Aromatase inhibitors (AIs) are a class of drugs that ... These medications have gained attention in the treatment of short stature, particularly in children experiencing growth disorders during ...

Aromatase inhibitors (AIs) are a common treatment for hormone receptor-positive breast cancer in postmenopausal women. While they are effective in improving survival rates, many patients ...

Table 1. Summary of medical therapy (chemotherapy and aromatase inhibitors) and measurements of cognitive functioning (neuropsychological testing and functional imaging) and potential ...

But she notes that researchers still don't know which strategy works best: taking an aromatase inhibitor instead of tamoxifen, as the first course of therapy after surgery for breast cancer ...

"CDK4/6 inhibitors have been a critical addition to standard endocrine therapy with aromatase inhibitors, and if progression occurs, combining a SERD with a CDK4/6 inhibitor can be beneficial.

One of the most common drugs used for hormonal therapy for breast cancer is Tamoxifen. A new group of hormonal therapies called aromatase inhibitors may also be an option.

Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...

Arimidex has also been approved as adjuvant therapy -- drugs given after surgery or radiation-- for women with certain types of early breast cancer. Aromatase inhibitors work differently than ...

A research team at the ICR has now identified a set of new biomarkers that A predictive test for personalising breast cancer treatment predict resistance to aromatase inhibitors in ER+/HER2+ tumours ...